The global Bioprocess Technology Market is gaining momentum as biopharmaceutical companies, contract manufacturers, academic institutions, and research laboratories invest in more efficient ways to produce biologics, vaccines, and cell and gene therapies. The market is shaped by rising pharmaceutical R&D spending, a growing burden of chronic diseases, and the need for cost-effective, scalable manufacturing. Bioprocess technologies, from cell culture media to chromatography systems and single-use consumables, are now central to modern biotherapeutic development and production.
According to The Insight Partners, the global bioprocess technology market was valued at US$ 30.9 billion in 2022 and is projected to reach US$ 77.09 billion by 2028, registering a compound annual growth rate (CAGR) of 16.8% during 2023–2028. The report also estimates the total addressable market at approximately US$ 330.61 billion over the 2023–2028 period. Growth is supported by rising R&D investment in new drug compounds, increasing demand for biologics and biosimilars, and the adoption of advanced manufacturing technologies. Innovation in single-use systems, automation, and process analytics is creating opportunities for manufacturers seeking to strengthen their market positions.
Download Sample PDF @ https://www.theinsightpartners.com/sample/TIPHE100001373
Technology and Application Landscape
Bioprocess technology is a core part of biotechnology. It uses living cells or their components, such as bacteria, enzymes, and proteins, together with nutrients to produce specialty chemicals, reagents, and biotherapeutics. The workflow runs from media preparation and biocatalyst selection through volume production, downstream processing, purification, and final processing. Its applications span pharmaceuticals, food, fuels, and chemicals.
Based on type, the market is segmented into cell culture media bioprocess, chromatography bioprocess, consumables and accessories, and others. Cell culture media bioprocess held the largest share in 2022, while chromatography bioprocess is expected to register the highest CAGR during the forecast period. Consumables and accessories also remain a major equipment category, accounting for a significant share of the market.
By modality, the market is divided into single-use and multiple-use systems. Single-use technologies held the larger share in 2022 because they reduce contamination risk, shorten turnaround times, and lower cleaning and validation requirements. Multiple-use systems are expected to grow at a higher CAGR over the forecast period.
By end user, the market covers academic and medical institutions, biopharmaceutical companies, research laboratories, and others. Biopharmaceutical companies accounted for the largest share in 2022, at 52.4%, while academic and medical institutions are expected to register a higher CAGR through 2028.
By application, the cancer segment is expected to be the fastest-growing, with a CAGR of 14.5%. Demand for biologic therapies is increasing as oncology pipelines expand.
Technological Developments
Technological advancement is an important trend shaping the bioprocess technology market. Manufacturers and research organizations are focusing on automation, process control, and analytics to improve yield, consistency, and regulatory compliance.
One important area is the shift toward single-use bioprocessing. Patent expiries of blockbuster drugs, limited late-stage pipelines, and rising demand for biologics are pushing companies to adopt technologies that enable faster, cost-effective production. Single-use components are typically manufactured and assembled in clean rooms to avoid introducing particulates and endotoxins into the process.
Process analytical technologies (PAT) are another key focus. Regulators strongly encourage them, and they are viewed as an enabler of real-time release and Bioprocessing 4.0. In June 2022, Merck entered a collaboration with Agilent Technologies to advance PAT. The emergence of Automated Real-Time Flow Cytometry (ART-FCM) is also identified as a future trend that may support the market during 2023–2028.
Automation and integrated platforms are also gaining attention. In March 2020, Sartorius launched the BIOSTAT STR Generation 3 single-use bioreactor and the BIOBRAIN automation platform to simplify biologics production and process development.
Cell and gene therapies are creating further demand. These therapies are changing how rare diseases are treated, and the FDA currently has more than 900 investigational new drug applications for gene therapy products underway, with 10–20 gene therapies approved annually. This supports demand for flexible, scalable bioprocess platforms.
Growing R&D spending is an additional driver. Large pharmaceutical companies continue to invest heavily in new molecules, and this spending supports the development of bioprocessing technologies and the interoperability of raw materials, bioreactors, and unit operations.
Regional Growth
The global bioprocess technology market is analyzed across North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. The Insight Partners evaluates regional dynamics based on factors influencing demand, market development, and opportunities for bioprocess technologies.
North America dominated the market in 2022 with a 49% share. The region benefits from the presence of large players, frequent product launches, advanced technology adoption, and favorable regulations for product approvals. The United States is the largest market in the region and is projected to grow at a CAGR of 14.3% over the forecast period.
Europe contributes through its strong biopharmaceutical manufacturing base, research activity, and established regulatory framework. Countries covered include the UK, Germany, France, Russia, Italy, and the Rest of Europe.
Asia Pacific is expected to be the fastest-growing region, with a CAGR of about 15%. China holds a considerable share in the region. Global bioprocessing capacity has increased by an average of about 12% over the past decade, and China’s biomanufacturing capacity is estimated at around 1.77 million liters, roughly 10.2% of global capacity, with an estimated capacity CAGR of 15–20%. Contract development and manufacturing organizations (CDMOs) play an important role in the country’s cell and gene therapy sector. Countries covered include China, India, Japan, and Australia.
South and Central America form part of the global assessment, with coverage of Brazil, Argentina, and other markets across the region.
The Middle East and Africa are also covered, including South Africa, Saudi Arabia, the United Arab Emirates, and other regional markets, where development depends on healthcare investment and access to advanced biomanufacturing.
Across these regions, continued R&D, expanding biomanufacturing capacity, and supportive regulatory environments may influence future market growth.
Key Players
The competitive landscape of the bioprocess technology market includes life science tools providers, bioprocess equipment manufacturers, and companies supplying media, consumables, and purification solutions. Market participants focus on product innovation, capacity expansion, strategic partnerships, and technology collaborations to strengthen their presence.
According to The Insight Partners, key companies profiled in the bioprocess technology market report include Merck KGaA, Sartorius AG, Thermo Fisher Scientific Inc, Corning Inc, STAMM Biotech, Lonza Group AG, Eppendorf SE, Repligen Corp, Danaher Corp, and BioPharma Dynamics Ltd.
These companies operate in a market where product quality, process reliability, scalability, and regulatory compliance are important competitive factors. Continued investment in R&D may help manufacturers improve system performance and explore new approaches to biologics production.
Strategic collaborations between manufacturers, technology providers, and research institutions can also support innovation. Partnerships such as the Merck and Agilent collaboration on process analytical technologies show how companies are working to strengthen technical capabilities and address evolving customer needs.
At the same time, the industry must navigate stringent regulatory requirements, which are identified as a restraining factor. Compliance with global GMP standards, process validation requirements, and product approval pathways adds complexity to technology development and commercialization.
Get Full Copy @ https://www.theinsightpartners.com/buy/TIPHE100001373
Future Outlook
The future outlook for the bioprocess technology market is closely linked to the increasing need for biologics, rising R&D investment, and continuous technological innovation. The growing prevalence of chronic diseases is creating demand for biotherapeutics, and bioprocess technologies are essential to producing them efficiently and at scale.
According to The Insight Partners, the global bioprocess technology market is projected to grow from US$ 30.9 billion in 2022 to US$ 77.09 billion by 2028, registering a CAGR of 16.8% during 2023–2028. The report identifies growing R&D spending on new drug compounds and the rising prevalence of chronic diseases as major factors supporting growth, while stringent regulatory policies remain a restraint.
Technological advancements are expected to remain an important influence. Improvements in single-use systems, automation, process analytics, and real-time monitoring may contribute to more efficient, flexible, and compliant biomanufacturing. These developments are creating opportunities for manufacturers and research institutions working to improve bioprocess capabilities.
Growing investment in cell and gene therapies, biologics, and biosimilars is another important opportunity. Collaboration among equipment makers, CDMOs, universities, and research organizations can help advance process development, improve affordability, and expand manufacturing capacity across regions.
The market’s future development will also depend on the ability of manufacturers and healthcare systems to meet regulatory requirements, manage technical challenges, and expand access to advanced biotherapeutics. Companies that prioritize R&D, improve product functionality, and build effective partnerships may be better positioned to capitalize on emerging opportunities.
Overall, the bioprocess technology market is expected to remain an important area of life sciences development as biopharmaceutical companies continue to scale up production of advanced therapies. The combination of growing clinical demand, technological innovation, and R&D investment is expected to influence the market throughout the forecast period.
Related Reports –
Bioprocess Containers Market Key Players Analysis, Opportunities, and Growth Forecast by 2031
Bioreactors Market Analysis, Size, and Share by 2030
Bioprocessing Market Analysis and Opportunities by 2031
About Us
The Insight Partners, we provide comprehensive analysis and insights into market trends that empower businesses to make informed decisions. Our reports are designed to equip stakeholders with the necessary information to navigate the complexities of various industries, including healthcare, technology, and finance. We are dedicated to delivering high-quality research that enables our clients to achieve their strategic objectives.
Contact Us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876
Also Available in : Korean German Japanese French Chinese Italian Spanish
